Design Therapeutics, Inc. (DSGN) SEC Filings & Earnings Calls

Clinical trial execution risk; data readout delays.

“FECD trial data delayed to 2027 due to supply issue.”

Clinical Trial Risk

“We are early in our development efforts, with three product candidates in clinical development and with all of our other research programs currently in the nonclinical or discovery stage.” · word for word

Financing Risk

“The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders.” · word for word

Regulatory Risk

“The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements.” · word for word

Early-stage clinical data; results may change with additional patients and follow-up.

“The data results described herein are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data and such data may not accurately reflect the complete results of the trial.” · word for word

Transient ALT elevations observed; potential safety signal.

“mild to moderate transient alanine transaminase (ALT) elevations observed in three patients, all of which were asymptomatic with no associated increases in bilirubin” · word for word

Clinical Development Risk

“We are early in our development efforts, with three product candidates in clinical development and with all of our other research programs currently in the nonclinical or discovery stage.” · word for word

Net Losses and No Revenue

“We have incurred net losses since our inception and as of March 31, 2026 had an accumulated deficit of $314.6 million.”

Regulatory Uncertainty

“In June 2025, we received a clinical hold notice from the FDA regarding our IND application for DT-216P2.” · word for word

Dependence on Key Personnel

“We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.” · word for word

Clinical trial failure risk; no approved products; reliance on pipeline success.

“Clinical-stage biotech with no revenue; all programs in development.”

Pre-revenue biotech with no approved products

“No product revenue or commercial-stage disclosure; all compensation tied to R&D milestones.”

Clinical trial failure risk

“Nonclinical and clinical development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of nonclinical studies and clinical trials may not be predictive of future trial results.” · word for word

Novel technology risk

“Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.” · word for word

No product revenue or profitability

“We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future.” · word for word

Pre-revenue biotech; clinical and regulatory risks for pipeline.

“No approved products; pipeline in Phase 1/2.”

Loss of board member, though not performance-related.

“Resignation due to conflict-of-interest policies.”

Pre-revenue biotech with clinical-stage pipeline; regulatory and trial risk.

FDA clinical hold on lead asset

“In June 2025, we received a clinical hold notice from the FDA regarding our IND application for DT-216P2.” · word for word

No revenue and increasing losses

“We have incurred net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.”

Dependence on single platform technology

“All of our product candidates and development programs are based on the same GeneTAC ® platform technologies, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other programs.” · word for word

Need for additional capital

“We believe that our existing cash, cash equivalents and investment securities will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates.” · word for word